Beth Aspel Winger, MD, PhD

Education

Professional Experience

• 1999
  Research intern, University of Texas Austin Department of Chemistry; Laboratory of Stephen F. Martin
• 1999 - 2000
  Undergraduate Thesis Research, Yale University Department of Chemistry, Laboratory of David Austin
• 2001 - 2002
  Fulbright Scholar, Manaaki Whenua Landcare Research, Alexandra
• 2002 - 2003
  Laboratory technician, New York University Department of Rheumatology, Laboratory of Michael Pillinger
• 2005 - 2005
  Rotation student, UCSF Department of Pharmacy and Pharmaceutical Sciences, Laboratory of James McKerrow
• 2005 - 2008
  Graduate student, UCSF Department of Chemistry and Chemical Biology, Laboratory of Kevan Shokat
• 2009 - present
  Lecturer and small group facilitator, UCSF School of Medicine, Cancer block
• 2010 - 2011
  Course Founder and Instructor, UCSF, MSTP-Into the Clinic!
• 2015 - 2019
  Fellow, UCSF Department of Medicine, Laboratory of Neil Shah
• 2018 - 2019
  Fellow, Accelerating Therapeutics for Opportunities in Medicine, San Francisco, CA
• 2018 - 2019
  Clinical Instructor, UCSF
• 2019 - present
  Assistant Professor, UCSF

Honors & Awards

• 1999
  Pfizer Synthetic Organic Chemistry Undergraduate Summer Research Fellowship
• 2000
  Richter Summer Fellowship, Yale University
• 2001
  Honors in Chemistry, Magna Cum Laude, Yale University
• 2001 - 2002
  Fulbright Graduate Student Award, Fulbright Association
• 2007 - 2008
  University of California Cancer Research Coordinating Committee Fellowship, University of California
• 2015
  Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research
• 2017 - 2020
  St. Baldrick's Foundation Fellowship Award, St. Baldrick's Foundation
• 2017 - 2020
  Frank A. Campini Foundation Award, Frank A. Campini Foundation
• 2020 - 2021
  Mary Anne Koda-Kimble Award for Innovation, UCSF
• 2020 - 2021
  Resource Allocation Program Grant (co-PI), UCSF

Selected Publications

1. Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. J Clin Pharmacol. 2020 May 31.
   View on PubMed
2. Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT. Cancer Res. 2019 08 15; 79(16):4283-4292.
   View on PubMed
3. Winger BA, Foy E, Sud SR, MacKenzie JD, Pua HH, Lau AH, Heyman MB, Laszik Z, Tureen J. Mycobacterium bovis Enterocolitis in an Immunocompromised Host. J Pediatr Gastroenterol Nutr. 2016 07; 63(1):e17-9.
   View on PubMed
4. Apsel Winger B, Shah NP. PPAR?: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411.
   View on PubMed
5. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009 Feb 10; 7(2):e38.
   View on PubMed
6. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov; 4(11):691-9.
   View on PubMed
7. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008 Aug 12; 14(2):180-92.
   View on PubMed
8. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des. 2006 May; 67(5):355-63.
   View on PubMed
9. Pillinger MH, Dinsell V, Apsel B, Tolani SN, Marjanovic N, Chan ES, Gomez P, Clancy R, Chang LF, Abramson SB. Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. Br J Pharmacol. 2004 Jul; 142(6):973-82.
   View on PubMed
10. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, Chan ES, Gomez PF, Abramson SB. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol. 2003 Dec 01; 171(11):6080-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI